STALICLA - Databased Endophenotyping Patient Identification (DEPI) Technology
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, proteomics, pharmacogenomics and clinical data.
- COMPUTING the complexity and heterogeneity of neurodevelopmental disorders
- IDENTIFYING relevant subgroups of patients with neurodevelopmental disorders
- ACCELERATING drug development for neurodevelopmental disorders
DEPI’s integration of metabolomics, whole-genome and RNA sequencing, and its proprietary HC match module are making headway in decoding NDDs’ underlying mechanisms and causal factors beyond behavioral-based diagnostics.
DEPI has reached clinical proof of concept with the clinical validation of a first enriched population. The matching pipeline candidate, STP1, is currently in Phase 1b clinical trials.
STALICLA is currently advancing the validation of two other ASD subgroups and their corresponding treatment candidates. Phenotype 2 and matching asset STP2 should enter clinical trials in 2022. DEPI is also supporting the identification of responding populations to third party assets.
Given that ASD and other NDDs often co-occur, therapies that address biological subgroups of ASD are also likely to benefit patients with other NDDs and similar biology.
Once a drug or drug combination is identified as a potential candidate, STALICLA validates its approach through clinical and laboratory studies using patient cells.
